Vancomycin 265/309 (85.8%) 76/265 (25.3%) 198/309 (64.1%) † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin: 200 mg twice a day; vancomycin ...

MRSA was once eradicated reliably by vancomycin (Vancocin AE), an antibiotic of the glycopeptide class. With time, the MRSA bacteria became resistant to vancomycin and vancomycin-resistant ...

Aster. None of these patients had a rise in the platelet count until the vancomycin was discontinued and an alternative antibiotic started. The vancomycin was stopped early in the remaining 14 ...

The growth of the vancomycin market is driven by several key factors, including the increasing prevalence of antibiotic-resistant infections, advancements in pharmaceutical manufacturing ...

Antibiotics such as vancomycin require careful monitoring and dosing regimens that take into account patient-specific factors impacted by the drug’s pharmacokinetics and pharmacodynamics ...

Anti-anaerobic antibiotic treatment was associated with ... (Patients with repeated admissions, who did not receive ...

difficile infections. The drug of choice for most patients is vancomycin, but in about one-third of patients, their infection returns within a month after they've finished treatment. One possible ...

Clostridioides difficile (C. diff), a type of bacteria which often affects people who have taken antibiotics, is responsible for approximately 2,000 deaths annually in the UK. Researchers from the ...

Immuron Limited (IMRN), an Australian-based biopharmaceutical company, Wednesday, announced a new research collaboration with Monash ...

The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial resistant pathogens. This work will utilize the Immuron technology platform, ...